Log in to your Inderes Free account to see all free content on this page.
Create account

Lärkberget

1.85 SEK

+0.54 %

Less than 1K followers

LARK

First North Stockholm

Investment

Financials

+0.54 %
-12.14 %
-18.36 %
-18.36 %
-27.08 %
-23.12 %
-72.63 %
-78.04 %
-98.08 %

Lärkberget is a Swedish investment company. The company's main areas of activity are direct investments in low-risk instruments, investments in listed shares, funds and other liquid asset classes, as well as participation in bridge loans and guarantee commitments, investments in unlisted profitable companies, and reverse acquisitions. Lärkberget is headquartered in Stockholm.

Read more
Market cap
36.53M SEK
Turnover
168.85K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.6.
2026

General meeting '26

20.8.
2026

Interim report Q2'26

11.2.
2027

Annual report '26

ShowingAll content types
Third party research

CombiGene: Making place for new ventures - VH Corp

• All research activities discontinued • Notice of an extraordinary general meeting on February 20, 2025 • Q&A with chairman Luca Di Stefano After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities...

Lärkberget

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

CombiGene: Strategic consequences after CG01 - VH Corp

* Implementing cost savings and new priorities * New propositions from the main shareholder * Our revised fair value estimate is SEK 8.27 (12.19) per share In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again...

Lärkberget
Third party research

CombiGene: New priorities after strategic decision - VH Corp

* Terminating the CG01 programme * Implementing cost savings to prolong the financial runway * Our fair value estimate is under review Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway...

Lärkberget
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.